ANIK News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

AN

Mkt Cap

$267.6M

Volume

67.13K

Next Earnings

November 4th

Loading chart

AN

ANIKAnika Therapeutics Inc

ANIK

Pay with—

Available Balance0.00

AN

Mkt Cap

$276.9M

Volume

67.13K

Next Earnings

November 4th

Chart Financials Earnings News About Insider Filings

Novartis' Remibrutinib Delivers Positive Results in Late-Stage MS StudiesNovartis announced positive results from late-stage REMODEL-1/-2 studies showing remibrutinib, a BTK inhibitor, significantly reduced annualized relapse rates versus Aubagio in relapsing multiple sclerosis patients. The drug also reduced inflammatory brain lesions with a favorable safety profile. Novartis plans global regulatory filings and will present data at MSToronto2026. Shares gained 6% on the news.Zacks Investment Research · Sep 2, 2026

GSK to Advance mRNA Influenza Vaccine Into Phase III DevelopmentGSK announced it will begin a Phase III efficacy study of its mRNA-based seasonal flu vaccine in September 2026, following positive Phase II results showing higher immune responses than standard and high-dose flu vaccines. The vaccine uniquely targets both HA and NA antigens, unlike most existing flu vaccines. The FDA granted Fast Track designation to the candidate. Moderna's mFlusiva mRNA flu vaccine was recently approved by the FDA for adults 50+.Zacks Investment Research · Sep 2, 2026

Teva Seeks to Boost Neuroscience Portfolio With BioXcel Asset BidTeva Pharmaceutical has made a bid to acquire certain assets of BioXcel Therapeutics, including Igalmi (dexmedetomidine sublingual film) and the investigational BXCL501 formulation under FDA review for at-home treatment of acute agitation. Teva would pay $57.5 million upfront with up to $67.5 million in contingent payments. The acquisition aligns with Teva's neuroscience expansion strategy and Pivot to Growth initiative.Zacks Investment Research · Aug 31, 2026

Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Anika Therapeutics granted 3,360 restricted stock units to a newly hired non-executive employee on June 1, 2026, as part of their employment compensation package. The RSUs will vest in three equal installments over three years, subject to continuous service.GlobeNewswire Inc. · Jun 5, 2026

ANIKA INVESTIGATION REMINDER: Bragar Eagel & Squire, P.C. Reminds Anika Therapeutics Investors to Contact the Firm Regarding the Ongoing Investigation on Behalf of Anika StockholdersLaw firm Bragar Eagel & Squire is investigating Anika Therapeutics for potential securities law violations following the failure of its Hyalofast clinical trial to meet pre-specified endpoints. The announcement on July 30, 2025, caused Anika's stock to plummet 27.42% to $8.10 per share. The firm is seeking investors who suffered losses to participate in the action.GlobeNewswire Inc. · Jan 26, 2026

Anika Therapeutics, Inc. INVESTIGATION: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud on behalf of Investors ANIKLaw firm investigating potential securities fraud at Anika Therapeutics after clinical trial results showed missed endpoints, causing stock price to drop 27.42% on July 30, 2025.GlobeNewswire Inc. · Dec 6, 2025

ANIKA (ANIK) ALERT: Bragar Eagel & Squire, P.C. is Investigating Anika Therapeutics, Inc. on Behalf of Anika Stockholders and Encourages Investors to Contact the FirmAnika Therapeutics announced clinical trial results for Hyalofast that did not meet pre-specified endpoints, causing a 27.42% stock price drop and triggering a potential legal investigation.GlobeNewswire Inc. · Sep 25, 2025

Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Anika Therapeutics granted 2,500 non-statutory stock options to a newly hired non-executive employee at $9.15 per share, with a vesting schedule over three years and a ten-year expiration.GlobeNewswire Inc. · Sep 5, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anika Therapeutics, Inc. - ANIKPomerantz LLP is investigating potential securities fraud at Anika Therapeutics after the company reported unsuccessful clinical trial results for Hyalofast, causing a 27.42% stock price drop.GlobeNewswire Inc. · Aug 17, 2025

ANIKA (ANIK) ALERT: Bragar Eagel & Squire, P.C. Continues Investigating Anika Therapeutics, Inc. on Behalf of Anika Stockholders and Encourages Investors to Contact the FirmAnika Therapeutics announced topline results from a U.S. pivotal clinical trial of Hyalofast, which did not meet pre-specified co-primary endpoints, causing a 27.42% stock price drop.GlobeNewswire Inc. · Aug 12, 2025

to start trading

AN

ANIKAnika Therapeutics Inc

ANIK

Pay with—

Available Balance0.00

Your PositionYou don't own any ANIK yet.

Related Tickers

Earnings